Fig. 1From: The unique characteristics of COVID-19 coagulopathyThrombus formation in disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. In bacterial sepsis, immune cells such as monocyte and macrophages are activated by pathogen-associated molecular patterns (PAMPs) and host-derived damage-associated molecular patterns (DAMPs). The immune cells initiate coagulation cascades through expressing tissue factor (TF) and releasing extracellular vesicles (EVs). The activated neutrophils and neutrophil extracellular traps (NETs) are also involved in coagulation. Degradation of fibrin, the end product of coagulation activation, is suppressed by increased levels of plasminogen activator inhibitor-1 (PAI-1). In thrombotic thrombocytopenic purpura (TTP), increased high multimers of von Willebrand factor (VWF) caused by ant-ADAMTS13 antibodies stimulate platelet aggregation. In hemolytic uremic syndrome (HUS), dysregulated complement system and its terminal product, membrane attack protein (MAC), damage vascular endothelial cells, and initiate clot formationBack to article page